Introduction
============

Gastric cancer (GC) is the third leading cause of cancer-associated mortality worldwide and the high incidence of GC poses a major threat to public health globally ([@b1-ol-0-0-11871]). At present, GC may be cured by radical resection; however, for patients with advanced-stage disease that can no longer receive radical surgical treatment, the median survival time after treatment with trastuzumab plus chemotherapy is only 13.8 months, the improvement of which poses a challenge to scientists and oncologists ([@b2-ol-0-0-11871]). Therefore, it is necessary to identify patients with poor prognosis as soon as possible, which will help doctors optimize treatment programs and improve the prognosis and quality of life of patients with advanced GC. The Union for International Cancer Control TNM classification system is one of the most common methods used by clinicians to evaluate the prognosis of patients with GC ([@b3-ol-0-0-11871]). However, this system has certain limitations, such as the fact that patients with the same tumor stage may have different clinical outcomes ([@b4-ol-0-0-11871],[@b5-ol-0-0-11871]). Therefore, it is imperative to identify other independent prognostic markers for GC to further classify patients who have been staged according to the TNM system into subgroups with good and poor prognosis. The addition of other well-proven markers should enable doctors to treat patients with poor prognosis in a more timely and effective manner.

Tumorigenesis is a multifactorial process. Hypercoagulability, inflammation and malnutrition promote the occurrence, development, recurrence and metastasis of tumors and are associated with poor treatment outcomes ([@b6-ol-0-0-11871]--[@b11-ol-0-0-11871]). Analysis of existing data has demonstrated that conditions of hypercoagulability, inflammation and poor nutritional status are independent prognostic factors for poor prognosis of patients with GC. As a marker reflecting coagulation function nutritional and the inflammatory status of patients, several studies have used the fibrinogen-to-albumin ratio (FAR) or albumin-to-fibrinogen ratio (AFR) to evaluate the prognosis of various cancer patients, including those with GC, and have found that increased FAR or decreased AFR levels were associated with poor prognosis in cancer patients ([@b12-ol-0-0-11871]--[@b17-ol-0-0-11871]). Another critical role of FAR or AFR is to assess the effect of the chemotherapy regimen in a particular population to guide the selection of an optimal therapy ([@b18-ol-0-0-11871]--[@b20-ol-0-0-11871]). However, there are currently few reports on the pretreatment FAR being used as a marker to predict progression-free survival (PFS) and overall survival (OS) in patients with GC undergoing first-line chemotherapy.

The aim of the present study was to investigate whether the pretreatment FAR may serve as a multifunctional marker for predicting PFS and OS in patients with advanced GC receiving first-line chemotherapy.

Materials and methods
=====================

### Patient characteristics

The data of patients with non-resectable GC from the Cancer Hospital of China Medical University (Shenyang, China) between January 2014 and January 2019 were retrospectively evaluated. All patients included were required to fulfill the following criteria: i) The diagnosis was pathologically confirmed; ii) the TNM stage for patients with GC unable to undergo radical resection was considered only as stage III--IV; iii) the patients included in the data collection received no adjuvant chemoradiotherapy; iv) no severe coagulation disorders, nutritional therapy, acute infections or other inflammatory conditions prior to specimen collection; and v) blood sample collection performed within 1 week prior to the initial first-line chemotherapy. A total of 273 patients with advanced GC meeting the inclusion criteria were included in the present retrospective study, 183 of whom were male and 90 were female. The study protocol was approved by the Cancer Hospital of China Medical University Ethics Committee (Shenyang, China).

### Clinical data collection and follow-up

In all patients included in the study, computed tomography, magnetic resonance imaging or other accepted imaging examinations were used to determine the presence of metastatic lymph nodes and organs. The reference range for plasma fibrinogen, albumin and hemoglobin was 2--4, 35--55 and 115--155 g/l, respectively. The accepted normal range for carcinoembryonic antigen, CA19-9 and CA72-4 was 0--5 ng/ml, 0--37 U/ml and 0--6 U/ml, respectively. The FAR was calculated as follows: FAR=fibrinogen (g/l)/albumin (g/l) ×100%.

The primary chemotherapeutic regimens for patients receiving first-line chemotherapy are as follows: SOX (oxaliplatin + S1)/CapeOX (oxaliplatin + capecitabine), FOLFOX (oxaliplatin + leucovorin + 5-fluorouracil) and DCF (docetaxel + cisplatin + 5-fluorouracil)/DOF (docetaxel + oxaliplatin + 5-fluorouracil). A total of 137 patients received SOX/CapeOX regimen, 49 patients received FOLFOX regimen, 36 patients received DCF/DOF regimen and 51 patients received S1 or capecitabine monotherapy. The efficacy of treatment was evaluated every 2--3 cycles. The Response Evaluation Criteria in Solid Tumors version 1.1 were employed to estimate the response to chemotherapy ([@b21-ol-0-0-11871]). Patients with first-line chemotherapy failure were followed up every 2--3 months. The latest follow-up date was December 2019. PFS and OS were considered as the primary endpoints. PFS was defined as the time from start of first-line chemotherapy until the first observed progression or the last follow-up visit without progression, while OS was defined as the time from the beginning of first-line chemotherapy to death from any cause or the end of follow-up.

### Statistical analysis

Data analysis was performed using SPSS v21 (IBM, Corp.). Receiver operating characteristic (ROC) curve analysis was applied to calculate the cut-off values of the FAR, fibrinogen and albumin. Fisher\'s exact test and the χ^2^ test were employed to evaluate the association between the FAR and the clinicopathological characteristics. Univariate and multivariate data analyses were conducted to identify potential predictors of PFS and OS. The Kaplan-Meier method was used to construct survival curves. The survival of patients was compared with the log-rank test. P\<0.05 was considered to indicate a statistical significant difference.

Results
=======

### Optimal cut-off value of the FAR

In addition to the FAR, the present study also assessed fibrinogen and albumin to determine whether the FAR is superior to either fibrinogen or albumin alone in predicting the prognosis of patients with GC. The area under the ROC curve (AUC) is considered to indicate the overall diagnostic power of a model, with a larger AUC indicating better diagnostic power of the prognostic predictor. In order to assess the ability of the FAR to discriminate between patients with advanced GC with different prognosis, ROC curve analysis was performed to determine the optimal cut-off values of the FAR, fibrinogen and albumin, and the AUC values of these three indicators were further compared. The median overall survival of 339 days was used as the fixed variable and the levels of FAR, fibrinogen and albumin as the test variables to determine the cut-off values. The optimal cut-off values of the FAR, fibrinogen and albumin were 10.033, 3.795 and 40.550, respectively. The FAR had a higher AUC value (0.690; 95% CI: 0.628--0.752; P\<0.001) compared with fibrinogen (0.657; 95% CI: 0.593--0.721; P\<0.001) and albumin (0.660; 95% CI: 0.596--0.724; P\<0.001; [Fig. 1](#f1-ol-0-0-11871){ref-type="fig"}), which indicated that the FAR is likely superior to fibrinogen and albumin alone in predicting the prognosis of patients with GC. The cut-off values of the FAR, fibrinogen and albumin were set as 10.03, 3.80 and 40.55, respectively, in the further analyses and patients with FAR \>10.03, fibrinogen ≥3.80 and albumin ≥40.55 comprised the high-FAR group, whereas the remaining patients comprised the low-FAR group.

### Association of clinicopathological characteristics with the FAR

Of the 273 patients included in the present study, 183 (67.03%) were male and 90 (32.97%) were female. The median age was 60 years (range, 52--65 years) and the median body mass index was 21.6 kg/m^2^ (range, 19.6--23.6 kg/m^2^). There were 80 (29.30%) patients with peritoneal metastasis and 220 (80.59%) patients with stage IV disease. Patients with a CA72-4 level \>6 U/ml and hemoglobin \<115 g/l accounted for 57.51 and 38.46% of the total, respectively ([Table I](#tI-ol-0-0-11871){ref-type="table"}).

There were certain differences in the clinicopathological characteristics between the low-FAR and the high-FAR groups. An elevated FAR was significantly associated with peritoneal carcinomatosis (P=0.010), stage IV cancer (P=0.025), increased CA72-4 levels (P=0.027) and anemia (P=0.031). The clinicopathological characteristics of the patients are further described in detail in [Table I](#tI-ol-0-0-11871){ref-type="table"}.

### Prognostic factors indicating patient survival

As presented in [Table II](#tII-ol-0-0-11871){ref-type="table"}, univariate analyses revealed that metastasis in \>1 organ (P=0.003), peritoneal metastasis (P\<0.001), TNM stage IV (P=0.026) and increased CA72-4 levels (P=0.001) were significantly associated with shorter PFS, while increased albumin (P=0.003) and reduced fibrinogen (P\<0.001) and FAR (P\<0.001) levels were significantly associated with longer PFS. On multivariate analysis, only peritoneal metastasis (P=0.042), CA72-4 levels (P=0.013), albumin (P=0.048) and FAR (P=0.020) were indicated to be independently associated with PFS. As the P-value of FAR (P=0.020) was lower compared with that of fibrinogen (P=0.231) and albumin (P=0.048) alone, the FAR was considered as significantly more effective than either fibrinogen or albumin alone in predicting PFS in patients with GC.

As presented in [Table III](#tIII-ol-0-0-11871){ref-type="table"}, metastasis to \>1 organ (P=0.030), peritoneal metastasis (P\<0.001) and CA72-4 levels \>6 U/ml (P=0.033) were identified as risk factors adversely affecting the OS of patients with GC, while an age of \>60 years (P=0.040), fibrinogen \<3.8 g/l (P\<0.001), albumin ≥40.55 g/l (P\<0.001) and FAR ≤10.03 (P\<0.001) were indicated to be protective factors favorably affecting the OS of patients with GC on univariate analysis. The results of the multivariate analysis demonstrated that the OS of patients with GG was independently associated with peritoneal metastasis (P=0.019), albumin (P=0.016) and FAR (P=0.002). FAR (P=0.002) was superior to fibrinogen (P=0.938) and albumin (P=0.016) in predicting the OS of patients with GC.

### Survival analysis according to pretreatment FAR

The median PFS and OS of the patients included in the present study were 174 and 339 days, respectively. The low-FAR group had longer median PFS and OS compared with the high-FAR group (202 vs. 130 days, P\<0.001; and 376 vs. 270 days, P\<0.001, respectively; [Fig. 2](#f2-ol-0-0-11871){ref-type="fig"}).

### Survival analysis for the FAR according to the prognostic factor subtypes of GC

Previous studies demonstrated that distant metastasis, peritoneal infiltration, TNM stage IV disease and increased CA72-4 levels are crucial characteristics indicating unfavorable prognosis in patients with GC ([@b22-ol-0-0-11871]--[@b24-ol-0-0-11871]). Therefore, a subgroup analysis was performed to investigate whether the pretreatment FAR is able to further predict the outcomes of patients with GC with poor prognosis ([Fig. 3](#f3-ol-0-0-11871){ref-type="fig"}). The results suggested improved PFS and OS in the low-FAR group within the subgroups with \>1 metastatic organ (P=0.001 and P\<0.001), stage IV cancer (all P\<0.001) and elevated CA72-4 levels (P=0.001 and P\<0.001). Although GC patients with low FAR within the peritoneal invasion subgroup tended to have longer PFS and OS, there was no statistical insignificance (all P\>0.05) and this result may have been obtained due to the small sample size (n=80).

For patients with normal albumin and fibrinogen levels, clinicians may be prone to overlooking the coagulation, inflammation and nutritional status that may indicate the prognosis of such patients. Thus, a subgroup analysis was performed to investigate whether the FAR is able to provide a clue as to the prognosis of patients with normal albumin and fibrinogen indices. The results suggested that low FAR within normal plasma fibrinogen and albumin level subgroups of patients with GC was an indicator of longer PFS and OS (all P\<0.001; [Fig. 4](#f4-ol-0-0-11871){ref-type="fig"}).

Discussion
==========

Previous studies have reported the importance of the FAR in predicting the prognosis of different types of cancer ([@b25-ol-0-0-11871]--[@b29-ol-0-0-11871]). Zhang *et al* ([@b30-ol-0-0-11871]) indicated that a reduced AFR was an independent predictor of poor OS in surgical stage II and III GC. In the present study, it was determined that patients with GC and a high FAR had shortened OS. In other words, the previous and the present study suggested that patients with elevated fibrinogen levels and decreased albumin levels had poor prognosis. Therefore, the conclusion regarding the prognostic value of AFR and FAR for predicting the OS of patients with GC in these two studies are similar. However, the patient characteristics of the present cohort are different from those in the previous study: The patients of the present study had stage III--IV unresectable GC and all patients received first-line chemotherapy. To the best of our knowledge, the present study was the first study to indicate that the FAR may be an independent predictor of first-line chemotherapy-associated PFS and long-term OS in patients with advanced GC. Furthermore, the prognostic value of the FAR was more powerful compared with that of either fibrinogen or albumin alone. The most noteworthy result of the present study was that the subgroup analysis results demonstrated that the FAR may be a cost-effective and accessible marker for patients with poor prognosis to further predict the clinical outcomes of these populations. Furthermore, the FAR may be a reliable indicator for predicting the prognosis of patients with normal albumin and fibrinogen levels that may otherwise not draw the physicians\' attention. Therefore, physicians may be able to formulate personalized treatment patterns for patients with GC with different prognosis by effectively applying the FAR.

There is increasing and credible evidence that cancer-associated hypercoagulability, inflammation and malnutrition are highly prevalent among cancer patients. These abnormal conditions may weaken the response of tumor patients to treatment and promote the occurrence, development, metastasis and exacerbation of cancer ([@b31-ol-0-0-11871]--[@b36-ol-0-0-11871]). The potential mechanism may be as follows: First, patients with malignant tumors may occasionally be in a hypercoagulable state, which may manifest as venous thromboembolism and disseminated intravascular coagulation. Although thrombosis may not be common among patients with advanced cancer, systemic hypercoagulability is frequently observed. The coagulation cascade has a crucial role in tumor growth. Components involved in the hypercoagulable state provide a stable framework for the tumor extracellular matrix, which sets the conditions for angiogenesis, adhesion, migration and invasion of tumor cells. The interaction of coagulation cytokines may also impede the cytotoxicity of immune cells against tumor cells ([@b37-ol-0-0-11871]). Furthermore, cytokines may also induce tumor cell proliferation and invasion by mediating the adhesion between leukocytes and endothelial cells, which promotes inflammation ([@b38-ol-0-0-11871]).

Second, inflammation is a hallmark of cancer ([@b39-ol-0-0-11871]). Inflammation may lead to mutagenesis, predisposing to the accumulation of mutations in tumor protein 53 and other cancer-associated genes and chronic inflammation that induces tissue damage may disrupt the barrier function, expose the stem cell region to environmental carcinogens or facilitate stem cells to be eroded by genotoxic compounds, which may trigger tumor formation ([@b40-ol-0-0-11871]). Kim *et al* ([@b41-ol-0-0-11871]) reported that tumor necrosis factor (TNF)-α and Toll-like receptor family member-2 (TLR2) may be essential for cancer metastasis. Cancer cells may trigger macrophage activity, which promotes the production of TNF-α by activating TLR2. The extracellular matrix proteoglycan versican, which is elevated in tumors, augments metastatic cancer growth by triggering TLR2 complexes and causing TNF-α release. These factors create an inflammatory microenvironment, which promotes metastatic growth ([@b41-ol-0-0-11871]).

Finally, malnutrition is universal among cancer patients receiving oncological treatment. Patients suffering from malnutrition have lower tumor treatment completion rates, poorer quality of life and more complications, which ultimately leads to lower survival rates ([@b42-ol-0-0-11871]). Malnutrition may cause fluctuation in the bone marrow stromal microenvironment, debilitate hematopoiesis and trigger thymic atrophy through apoptosis of immature CD4/CD8 double-positive thymocytes, thereby promoting a decline in immunity, which facilitates the proliferation of tumor cells ([@b43-ol-0-0-11871]).

Previous studies have demonstrated that anti-coagulant therapy, anti-inflammatory treatment and nutritional support may reduce susceptibility to cancer, prevent disease exacerbation and improve the clinical outcome ([@b44-ol-0-0-11871]--[@b46-ol-0-0-11871]). As a reliable prognostic indicator, the FAR relies on fibrinogen and albumin. Fibrinogen is an acute-phase protein produced by the liver and its plasma levels increase under hypercoagulable and inflammatory conditions ([@b47-ol-0-0-11871]--[@b49-ol-0-0-11871]). A large body of evidence indicated that fibrinogen-related coagulation dysfunction is tightly linked to cancer angiogenesis, invasion, progression and metastasis ([@b50-ol-0-0-11871],[@b51-ol-0-0-11871]). Reliable data have demonstrated that elevated fibrinogen levels are associated with poor prognosis of patients with cancer, including GC ([@b52-ol-0-0-11871],[@b53-ol-0-0-11871]). Albumin is also produced by liver cells. The tumor-associated proinflammatory cytokines TNF-α and interleukin-6 are able to inhibit albumin production by hepatocytes ([@b54-ol-0-0-11871]). The decrease in plasma albumin levels indicates a high degree of inflammation, poor nutritional status and poor treatment efficacy ([@b55-ol-0-0-11871],[@b56-ol-0-0-11871]). Albumin has also been investigated for its potential value in predicting shorter survival in a number of cancer types, including GC ([@b57-ol-0-0-11871],[@b58-ol-0-0-11871]).

As mentioned above, albumin and fibrinogen are important prognostic indicators for patients with GC, but their accuracy may be compromised by certain factors, such as dehydration or fluid retention. The results of the present ROC curve analysis demonstrated that the AUC of the FAR (0.690) was higher compared with that of fibrinogen (0.657) and albumin (0.660), and the P-value of FAR (PFS: P=0.020; OS: P=0.002) was lower compared with that of fibrinogen (PFS: P=0.231; OS: P=0.938) and albumin (PFS: P=0.048; OS: P=0.016) on multivariate analyses, which indicated that the prognostic value of the FAR was superior to that of either fibrinogen or albumin alone.

Based on the results of the present study, clinicians may use the FAR to distinguish patients with poor prognosis and personalize treatment to improve their quality of life and prolong survival. There were certain limitations to the present study. First, as this was a single-center retrospective study, the usefulness of the FAR requires verification by multicenter large-scale studies. Furthermore, a total of 273 patients included in the present study, which is a small sample size and may be insufficient to draw definitive conclusions.

In conclusion, the FAR prior to first-line chemotherapy may help identify specific patient populations that are likely to benefit from chemotherapy and is an independent predictor of PFS and OS; therefore, it may be used as an innovative, dependable prognostic index for patients with advanced-stage GC.
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###### 

Association between pretreatment FAR and clinicopathological characteristics.

  Variable                           All           Low FAR       High FAR     P-value
  ---------------------------------- ------------- ------------- ------------ ---------
  Total                              273 (100.0)   175 (64.10)   98 (35.90)   
  Age (years)                                                                 0.057
    \<60                             135 (49.45)   79 (45.14)    56 (57.14)   
    ≥60                              138 (50.55)   96 (54.86)    42 (42.86)   
  Sex                                                                         0.726
    Male                             183 (67.03)   116 (66.29)   67 (68.37)   
    Female                           90 (32.97)    59 (33.71)    31 (31.63)   
  Body mass index (kg/m^2^)                                                   0.965
    \<18.5 or \>25                   72 (26.37)    46 (26.29)    26 (26.53)   
    18.5--25                         201 (73.63)   129 (73.71)   72 (73.47)   
  ECOG PS score                                                               0.695
    0-1                              228 (83.52)   145 (82.86)   83 (84.69)   
    \>1                              45 (16.48)    30 (17.14)    15 (15.31)   
  Histological differentiation                                                0.050
    High/moderate                    72 (26.37)    53 (30.29)    19 (19.39)   
    Poor/mucinous                    201 (73.63)   122 (69.71)   79 (80.61)   
  Number of organs with metastasis                                            0.486
    0-1                              180 (65.93)   118 (67.43)   62 (63.27)   
    \>1                              93 (34.07)    57 (32.57)    36 (36.73)   
  Peritoneal metastasis                                                       0.010
    Yes                              80 (29.30)    42 (24.00)    38 (38.78)   
    No                               193 (70.70)   133 (76.00)   60 (61.22)   
  TNM stage                                                                   0.025
    III                              53 (19.41)    41 (23.43)    12 (12.24)   
    IV                               220 (80.59)   134 (76.57)   86 (87.76)   
  CEA (ng/ml)                                                                 0.691
    ≤5                               152 (55.68)   99 (56.57)    53 (54.08)   
    \>5                              121 (44.32)   76 (43.43)    45 (45.92)   
  CA19-9 (U/ml)                                                               0.264
    ≤37                              168 (61.54)   112 (64.00)   56 (57.14)   
    \>37                             105 (38.46)   63 (36.00)    42 (42.86)   
  CA72-4 (U/ml)                                                               0.027
    ≤6                               116 (42.49)   83 (47.43)    33 (33.67)   
    \>6                              157 (57.51)   92 (52.57)    65 (66.33)   
  Hemoglobin (g/l)                                                            0.031
    \<115                            105 (38.46)   59 (33.71)    46 (46.94)   
    ≥115                             168 (61.54)   116 (66.29)   52 (53.06)   

Values are expressed as n (%). FAR, fibrinogen-to-albumin ratio; ECOG PS, Eastern Cooperative Oncology Group performance status.

###### 

Associations of PFS with FAR and other clinicopathological factors.

                                                Univariate analysis   Multivariate analysis                                    
  --------------------------------------------- --------------------- ----------------------- --------- ------- -------------- -------
  Age \>60 years                                0.988                 0.778--1.255            0.921                            
  Male sex                                      1.140                 0.884--1.471            0.313                            
  Body mass index                                                                                                              
  \<18.5 or \>25 kg/m^2^                        0.940                 0.717--1.231            0.651                            
  ECOG PS score \>1                             1.295                 0.940--1.784            0.114     1.164   0.832--1.629   0.376
  Histological differentiation, poor/mucinous   1.144                 0.873--1.500            0.329                            
  Metastasis in \>1 organ                       1.464                 1.138--1.883            0.003     1.232   0.920--1.651   0.162
  Peritoneal metastasis                         1.813                 1.388--2.367            \<0.001   1.370   1.011--1.857   0.042
  TNM stage IV                                  1.412                 1.042--1.913            0.026     1.060   0.759--1.481   0.731
  CEA \>5 ng/ml                                 1.162                 0.913--1.480            0.223                            
  CA19-9 \>37 U/ml                              0.972                 0.761--1.243            0.823                            
  CA72-4 \>6 U/ml                               1.506                 1.178--1.926            0.001     1.375   1.068--1.770   0.013
  Hemoglobin \<115 g/l                          0.919                 0.718--1.176            0.502                            
  Fibrinogen \<3.8 g/l                          0.567                 0.441--0.729            \<0.001   0.805   0.564--1.149   0.231
  Albumin ≥40.55 g/l                            0.697                 0.547--0.887            0.003     0.770   0.595--0.998   0.048
  FAR ≤10.03                                    0.468                 0.360--0.608            \<0.001   0.638   0.436--0.932   0.020

FAR, fibrinogen-to-albumin ratio; PFS, progression-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.

###### 

Associations of OS with FAR and other clinicopathological factors.

                                                Univariate analysis   Multivariate analysis                                    
  --------------------------------------------- --------------------- ----------------------- --------- ------- -------------- -------
  Age \>60 years                                0.778                 0.612--0.989            0.040     0.869   0.674--1.120   0.278
  Male sex                                      1.136                 0.881--1.465            0.324                            
  Body mass index                                                                                                              
  \<18.5 or \>25 kg/m^2^                        1.014                 0.774--1.329            0.921                            
  ECOG PS score \>1                             1.304                 0.946--1.798            0.105     1.196   0.858--1.668   0.291
  Histological differentiation, poor/mucinous   1.268                 0.968--1.661            0.084     1.096   0.832--1.444   0.516
  Metastasis in \>1 organ                       1.326                 1.028--1.709            0.030     1.166   0.884--1.537   0.277
  Peritoneal metastasis                         1.932                 1.478--2.524            \<0.001   1.441   1.063--1.955   0.019
  TNM stage IV                                  1.188                 0.879--1.605            0.263                            
  CEA \>5 ng/ml                                 1.123                 0.884--1.428            0.342                            
  CA19-9 \>37 U/ml                              1.072                 0.839--1.369            0.578                            
  CA72-4 \>6 U/ml                               1.301                 1.021--1.656            0.033     1.224   0.951--1.574   0.116
  Hemoglobin \<115 g/l                          0.932                 0.729--1.192            0.575                            
  Fibrinogen \<3.8 g/l                          0.628                 0.490--0.804            \<0.001   0.986   0.695--1.399   0.938
  Albumin ≥40.55 g/l                            0.635                 0.498--0.810            \<0.001   0.725   0.559--0.941   0.016
  FAR ≤10.03                                    0.463                 0.358--0.599            \<0.001   0.568   0.394--0.819   0.002

FAR, fibrinogen-to-albumin ratio; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.
